Efficacy and safety of lobeglitazone versus sitagliptin as an add-on to metformin in patients with type 2 diabetes with two or more components of metabolic syndrome over 24 weeks

Sin Gon Kim, Kyoung Jin Kim, Kun Ho Yoon, Sung Wan Chun, Kyong Soo Park, Kyung Mook Choi, Soo Lim, Ji Oh Mok, Hyoung Woo Lee, Ji A. Seo, Bong Soo Cha, Mi Kyung Kim, Ho Sang Shon, Dong Seop Choi, Doo Man Kim

    Research output: Contribution to journalArticlepeer-review

    2 Citations (Scopus)

    Abstract

    We aimed to evaluate the efficacy and safety profile of lobeglitazone compared with sitagliptin as an add-on to metformin in patients with type 2 diabetes as well as other components of metabolic syndrome. Patients inadequately controlled by metformin were randomly assigned to lobeglitazone (0.5 mg, n = 121) or sitagliptin (100 mg, n = 126) for 24 weeks. The mean changes in HbA1c of the lobeglitazone and sitagliptin groups were −0.79% and −0.86%, respectively; the between-group difference was 0.08% (95% confidence interval, −0.14% to 0.30%), showing non-inferiority. The proportion of patients having two or more factors of other metabolic syndrome components decreased to a greater extent in the lobeglitazone group than in the sitagliptin group (−11.9% vs. −4.8%; P <.0174). Favourable changes in the lipid metabolism were also observed with lobeglitazone, which had a similar safety profile to sitagliptin. Lobeglitazone was comparable with sitagliptin as an add-on to metformin in terms of efficacy and safety.

    Original languageEnglish
    Pages (from-to)1869-1873
    Number of pages5
    JournalDiabetes, Obesity and Metabolism
    Volume22
    Issue number10
    DOIs
    Publication statusPublished - 2020 Oct 1

    Keywords

    • clinical trial
    • lobeglitazone
    • randomized trial
    • thiazolidinediones
    • type 2 diabetes

    ASJC Scopus subject areas

    • Internal Medicine
    • Endocrinology, Diabetes and Metabolism
    • Endocrinology

    Fingerprint

    Dive into the research topics of 'Efficacy and safety of lobeglitazone versus sitagliptin as an add-on to metformin in patients with type 2 diabetes with two or more components of metabolic syndrome over 24 weeks'. Together they form a unique fingerprint.

    Cite this